JP7237064B2 - 単一免疫グロブリンインターロイキン－１受容体関連（ｓｉｇｉｒｒ）変異型及びその使用 - Google Patents

単一免疫グロブリンインターロイキン－１受容体関連（ｓｉｇｉｒｒ）変異型及びその使用 Download PDF

Info

Publication number
JP7237064B2
JP7237064B2 JP2020513609A JP2020513609A JP7237064B2 JP 7237064 B2 JP7237064 B2 JP 7237064B2 JP 2020513609 A JP2020513609 A JP 2020513609A JP 2020513609 A JP2020513609 A JP 2020513609A JP 7237064 B2 JP7237064 B2 JP 7237064B2
Authority
JP
Japan
Prior art keywords
nucleic acid
seq
sigirr
truncated
acid molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020513609A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020537495A (ja
JP2020537495A5 (cg-RX-API-DMAC7.html
Inventor
ジー． ゴンザガ－ハウレギ、クラウディア
ホロウィッツ、ジュリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2020537495A publication Critical patent/JP2020537495A/ja
Publication of JP2020537495A5 publication Critical patent/JP2020537495A5/ja
Application granted granted Critical
Publication of JP7237064B2 publication Critical patent/JP7237064B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2020513609A 2017-09-06 2018-09-05 単一免疫グロブリンインターロイキン－１受容体関連（ｓｉｇｉｒｒ）変異型及びその使用 Active JP7237064B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762554857P 2017-09-06 2017-09-06
US62/554,857 2017-09-06
PCT/US2018/049478 WO2019050899A1 (en) 2017-09-06 2018-09-05 SINGLE IMMUNOGLOBULIN INTERLEUKIN 1 (SIGIRR) RELATED INTERCEPTOR-RELATED VARIANTS AND USES THEREOF

Publications (3)

Publication Number Publication Date
JP2020537495A JP2020537495A (ja) 2020-12-24
JP2020537495A5 JP2020537495A5 (cg-RX-API-DMAC7.html) 2021-10-14
JP7237064B2 true JP7237064B2 (ja) 2023-03-10

Family

ID=63708447

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020513609A Active JP7237064B2 (ja) 2017-09-06 2018-09-05 単一免疫グロブリンインターロイキン－１受容体関連（ｓｉｇｉｒｒ）変異型及びその使用

Country Status (15)

Country Link
US (1) US20210071251A1 (cg-RX-API-DMAC7.html)
EP (1) EP3679158B1 (cg-RX-API-DMAC7.html)
JP (1) JP7237064B2 (cg-RX-API-DMAC7.html)
KR (1) KR102752108B1 (cg-RX-API-DMAC7.html)
CN (1) CN111373053B (cg-RX-API-DMAC7.html)
AU (1) AU2018328120B2 (cg-RX-API-DMAC7.html)
CA (1) CA3074652A1 (cg-RX-API-DMAC7.html)
DK (1) DK3679158T3 (cg-RX-API-DMAC7.html)
ES (1) ES3034207T3 (cg-RX-API-DMAC7.html)
FI (1) FI3679158T3 (cg-RX-API-DMAC7.html)
IL (1) IL272940B2 (cg-RX-API-DMAC7.html)
MX (1) MX2020002643A (cg-RX-API-DMAC7.html)
NZ (1) NZ762152A (cg-RX-API-DMAC7.html)
SG (1) SG11202001754RA (cg-RX-API-DMAC7.html)
WO (1) WO2019050899A1 (cg-RX-API-DMAC7.html)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001526892A (ja) 1997-12-23 2001-12-25 イミュネックス・コーポレーション Ｓｉｇｉｒｒｄｎａおよびポリペプチド

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5294533A (en) 1988-07-05 1994-03-15 Baylor College Of Medicine Antisense oligonucleotide antibiotics complementary to the macromolecular synthesis operon, methods of treating bacterial infections and methods for identification of bacteria
US5135917A (en) 1990-07-12 1992-08-04 Nova Pharmaceutical Corporation Interleukin receptor expression inhibiting antisense oligonucleotides
US5271941A (en) 1990-11-02 1993-12-21 Cho Chung Yoon S Antisense oligonucleotides of human regulatory subunit RI.sub.α of cAMP-dependent protein kinases
US5786138A (en) 1993-01-29 1998-07-28 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Hyperstabilizing antisense nucleic acid binding agents
AU693097B2 (en) 1993-06-04 1998-06-25 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Method for treating kaposi's sarcoma with antisense oligonucleotides
US5578716A (en) 1993-12-01 1996-11-26 Mcgill University DNA methyltransferase antisense oligonucleotides
US5641754A (en) 1994-01-10 1997-06-24 The Board Of Regents Of The University Of Nebraska Antisense oligonucleotide compositions for selectively killing cancer cells
EP0775204A1 (en) 1994-08-09 1997-05-28 Novartis AG Antitumor antisense oligonucleotides
US5856103A (en) 1994-10-07 1999-01-05 Board Of Regents The University Of Texas Method for selectively ranking sequences for antisense targeting
US5994320A (en) 1995-02-06 1999-11-30 Regents Of The University Of Minnesota Antisense oligonucleotides and methods for treating central nervous system tumors
IT1275862B1 (it) 1995-03-03 1997-10-24 Consiglio Nazionale Ricerche Trascritto antisenso associato ad alcuni tipi di cellule tumorali ed oligodeossinucleotidi sintetici utili nella diagnosi e nel trattamento
US6040296A (en) 1995-06-07 2000-03-21 East Carolina University Specific antisense oligonucleotide composition & method for treatment of disorders associated with bronchoconstriction and lung inflammation
WO1997014709A1 (en) 1995-10-13 1997-04-24 F. Hoffmann-La Roche Ag Antisense oligomers
JPH11507245A (ja) 1995-11-21 1999-06-29 アイシーエヌ・ファーマシューティカルズ・インコーポレイテッド Ｉｌ―８およびｉｌ―８受容体に対するアンチセンスオリゴヌクレオチドによる睡瘍増殖の阻害
AU708535B2 (en) 1996-02-15 1999-08-05 Cleveland Clinic Foundation, The RNase L activators and antisense oligonucleotides effective to treat RSV infections
US5955590A (en) 1996-07-15 1999-09-21 Worcester Foundation For Biomedical Research Conjugates of minor groove DNA binders with antisense oligonucleotides
US6046004A (en) 1997-02-27 2000-04-04 Lorne Park Research, Inc. Solution hybridization of nucleic acids with antisense probes having modified backbones
JPH1142091A (ja) 1997-07-25 1999-02-16 Toagosei Co Ltd アンチセンス核酸化合物
US6046319A (en) 1997-10-22 2000-04-04 University Technologies International, Inc. Antisense oligodeoxynucleotides regulating expression of TNF-α
US6007995A (en) 1998-06-26 1999-12-28 Isis Pharmaceuticals Inc. Antisense inhibition of TNFR1 expression
US6013522A (en) 1999-02-23 2000-01-11 Isis Pharmaceuticals Inc. Antisense inhibition of human Smad1 expression
US6025198A (en) 1999-06-25 2000-02-15 Isis Pharmaceuticals Inc. Antisense modulation of Ship-2 expression
US6033910A (en) 1999-07-19 2000-03-07 Isis Pharmaceuticals Inc. Antisense inhibition of MAP kinase kinase 6 expression
WO2013176772A1 (en) 2012-05-25 2013-11-28 The Regents Of The University Of California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
LT3138910T (lt) 2012-12-06 2017-11-10 Sigma-Aldrich Co. Llc Crispr pagrįstas genomo modifikavimas ir reguliavimas
EP4230648A3 (en) 2016-07-28 2023-10-18 Regeneron Pharmaceuticals, Inc. Gpr156 variants and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001526892A (ja) 1997-12-23 2001-12-25 イミュネックス・コーポレーション Ｓｉｇｉｒｒｄｎａおよびポリペプチド

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Cytokine，1999年，Vol.11, No.6，pp.389-399
Pediatrics，2015年，Vol.135, No.6，e1530-e1534

Also Published As

Publication number Publication date
IL272940B1 (en) 2024-02-01
SG11202001754RA (en) 2020-03-30
DK3679158T3 (da) 2025-06-23
CN111373053B (zh) 2024-07-30
JP2020537495A (ja) 2020-12-24
EP3679158B1 (en) 2025-04-30
FI3679158T3 (fi) 2025-06-18
RU2020112474A (ru) 2021-10-06
CN111373053A (zh) 2020-07-03
MX2020002643A (es) 2020-09-25
AU2018328120B2 (en) 2024-11-14
KR20200058435A (ko) 2020-05-27
NZ762152A (en) 2025-11-28
ES3034207T3 (en) 2025-08-13
CA3074652A1 (en) 2019-03-14
AU2018328120A1 (en) 2020-03-19
US20210071251A1 (en) 2021-03-11
KR102752108B1 (ko) 2025-01-10
WO2019050899A1 (en) 2019-03-14
EP3679158A1 (en) 2020-07-15
RU2020112474A3 (cg-RX-API-DMAC7.html) 2021-12-29
IL272940B2 (en) 2024-06-01
IL272940A (en) 2020-04-30

Similar Documents

Publication Publication Date Title
US11155598B2 (en) GPR156 variants and uses thereof
US20220017964A1 (en) Cornulin (CRNN) Variants And Uses Thereof
JP7237064B2 (ja) 単一免疫グロブリンインターロイキン－１受容体関連（ｓｉｇｉｒｒ）変異型及びその使用
RU2815068C2 (ru) Варианты белка, родственного рецептору интерлейкина-1 и содержащего одиночный домен иммуноглобулина (sigirr), и их применение
US20210230609A1 (en) Solute Carrier Family 14 Member 1 (SLC14A1) Variants And Uses Thereof
HK40033837A (en) Single immunoglobulin interleukin-1 receptor related (sigirr) variants and uses thereof
HK40033837B (en) Single immunoglobulin interleukin-1 receptor related (sigirr) variants and uses thereof
HK40098517A (en) Gpr156 variants and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210903

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210903

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220727

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220802

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230111

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230201

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230228

R150 Certificate of patent or registration of utility model

Ref document number: 7237064

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150